Abstract

Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The Success of Treatment Free Remission in Chronic Myeloid Leukaemia in Clinical Practice: A Single-Centre Retrospective Experience from South Africa.
Siddeeq Hoosen ... Manishekhar Kumar
Advances in hematology | VOL. 2023
Siddeeq Hoosen, et. al.Siddeeq Hoosen ... Manishekhar Kumar
28 Jul 2023
On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study
Anton Kulikovsky ... Anna G Turkina
Blood | VOL. 134
Anton Kulikovsky, et. al.Anton Kulikovsky ... Anna G Turkina
13 Nov 2019
Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML
Adelina Fernandes ... Timothy P Hughes
Blood | VOL. 142
Adelina Fernandes, et. al.Adelina Fernandes ... Timothy P Hughes
28 Nov 2023
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Agnès Guerci-Bresler ... Laurence Legros
Oncotarget | VOL. 7
Agnès Guerci-Bresler, et. al.Agnès Guerci-Bresler ... Laurence Legros
05 May 2016
View more papers

More From: British journal of haematology

Paper Title
Journal
Date
Author
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Tamer Othman ... Ibrahim Aldoss
British journal of haematology | VOL. -
Tamer Othman, et. al.Tamer Othman ... Ibrahim Aldoss
29 May 2024
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group.
Herbert Pichler ... Adriana Balduzzi
British journal of haematology | VOL. -
Herbert Pichler, et. al.Herbert Pichler ... Adriana Balduzzi
27 May 2024
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
Douglas A Stewart ... Michael Crump
British journal of haematology | VOL. -
Douglas A Stewart, et. al.Douglas A Stewart ... Michael Crump
27 May 2024
RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
Siyang Wang ... Kankan Wang
British journal of haematology | VOL. -
Siyang Wang, et. al.Siyang Wang ... Kankan Wang
27 May 2024
View more papers